Journal
ACTA OPHTHALMOLOGICA
Volume 99, Issue 7, Pages 805-811Publisher
WILEY
DOI: 10.1111/aos.14775
Keywords
central serous chorioretinopathy; long‐ term follow‐ up; micropulse laser; photodynamic therapy
Categories
Funding
- Stichting Macula Fonds
- Retina Nederland Onderzoek Fonds
- Stichting Blinden-Penning
- Algemene Nederlandse Vereniging ter Voorkoming van Blindheid
- Landelijke Stichting voor Blinden en Slechtzienden
- UitZicht (Delft, the Netherlands)
- Rotterdamse Stichting Blindenbelangen (Rotterdam, the Netherlands)
- Stichting Leids Oogheelkundig Ondersteuningsfonds (Leiden, the Netherlands)
- Haagse Stichting Blindenhulp (The Hague, the Netherlands)
- Stichting Ooglijders (Rotterdam, the Netherlands)
- Stichting Blindenhulp
- Oxford NIHR Biomedical Research Centre (Oxford, United Kingdom)
- Leiden University, Leiden, the Netherlands
- Netherlands Organization for Scientific Research (VENI)
- Novartis Pharma B.V. (Arnhem, the Netherlands)
Ask authors/readers for more resources
Following the completion of the PLACE trial, cCSC patients who were successfully treated with half-dose PDT were less likely to experience recurrences of SRF compared to those treated with HSML. However, there were no differences in functional outcomes between the two treatment groups.
Purpose To describe the treatment outcomes and recurrence risk of chronic central serous chorioretinopathy (cCSC) in patients who had complete resolution of subretinal fluid (SRF) after either primary half-dose photodynamic therapy (PDT) or high-density subthreshold micropulse laser (HSML) in the PLACE trial. Methods This multicentre prospective follow-up study evaluated cCSC patients at 1 year after completion of the PLACE trial. Outcomes included: complete resolution of SRF on OCT, best-corrected visual acuity (BCVA) in Early Treatment of Diabetic Retinopathy Study (ETDRS) letters, retinal sensitivity on microperimetry and a visual function questionnaire (NEI-VFQ25). Results Twenty-nine out of 37 patients who received half-dose PDT and 15 out of 17 patients who received HSML could be evaluated at final visit. At final visit, 93% of the patients treated with half-dose PDT had complete resolution of SRF, compared with 53% of HSML-treated patients (p = 0.006). At final visit, the mean estimate increase in the PDT group compared with the HSML group was + 2.1 ETDRS letters, +0.15 dB for the retinal sensitivity and + 5.1 NEI-VFQ25 points (p = 0.103, p = 0.784 and p = 0.071, respectively). The mean estimated central retinal thickness in the half-dose PDT group was -7.0 mu m compared with the HSML group (p = 0.566). The mean estimated subfoveal choroidal thickness in the half-dose PDT group was -16.6 mu m compared with the HSML group (p = 0.359). Conclusion At 20 months after treatment, cCSC patients successfully treated with half-dose PDT are less likely to have recurrences of SRF compared with those successfully treated with HSML. However, functional outcomes did not differ.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available